These theories are based on the available literature and our understanding of the pathophysiology of osteonecrosis of the jaw in patients on BPs and/or RANKL inhibitor and the effect of each on the soft tissues. The gene discussed is TNFSF11; the disease is Bartsocas-Papas syndrome 1.